Sara A Mansfield1,2, M Beth McCarville3, John T Lucas4, Matthew J Krasin4, Sara M Federico5, Victor M Santana5,6, Wayne L Furman5, Andrew M Davidoff7,8. 1. Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN, USA. sara.mansfield@stjude.org. 2. Division of Pediatric Surgery, Department of Surgery, University of Tennessee Health Science Center, Memphis, TN, USA. sara.mansfield@stjude.org. 3. Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN, USA. 4. Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. 5. Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. 6. Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN, USA. 7. Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN, USA. 8. Division of Pediatric Surgery, Department of Surgery, University of Tennessee Health Science Center, Memphis, TN, USA.
Abstract
PURPOSE: Image-defined risk factors (IDRFs) are associated with surgical risks in neuroblastoma. We sought to evaluate the impact of neoadjuvant therapy on IDRFs and associated ability to achieve gross total resection (GTR) of locoregional disease in patients with high-risk neuroblastoma. METHODS: We retrospectively reviewed charts of patients treated on four consecutive high-risk neuroblastoma protocols over a 20-year period at a single institution. The number of IDRFs at diagnosis and just prior to surgery, and the percent decrease of tumor volume from just prior to surgery to the end of induction were determined. RESULTS: Eighty-eight patients were included. There were 438 IDRFs (average 5.0 ± 3.1 per patient) at diagnosis and 198 (average 2.3 ± 1.9 per patient) after neoadjuvant chemotherapy (p < 0.01). A reduction in IDRFs was seen in 81.8% of patients with average decrease of 2.9 ± 2.5 per patient. The average percent reduction in tumor volume was 89.8 ± 18.9% and correlated with the number of IDRFs present after chemotherapy (p < 0.01). Three or fewer IDRFs prior to surgery was associated with the highest odds ratio for > 90% GTR at 9.33 [95% confidence interval 3.14-31.5]. CONCLUSION: Neoadjuvant chemotherapy reduced the number of IDRFs in the majority of patients with high-risk neuroblastoma. The number of IDRFs present after neoadjuvant therapy correlated with the extent of resection.
PURPOSE: Image-defined risk factors (IDRFs) are associated with surgical risks in neuroblastoma. We sought to evaluate the impact of neoadjuvant therapy on IDRFs and associated ability to achieve gross total resection (GTR) of locoregional disease in patients with high-risk neuroblastoma. METHODS: We retrospectively reviewed charts of patients treated on four consecutive high-risk neuroblastoma protocols over a 20-year period at a single institution. The number of IDRFs at diagnosis and just prior to surgery, and the percent decrease of tumor volume from just prior to surgery to the end of induction were determined. RESULTS: Eighty-eight patients were included. There were 438 IDRFs (average 5.0 ± 3.1 per patient) at diagnosis and 198 (average 2.3 ± 1.9 per patient) after neoadjuvant chemotherapy (p < 0.01). A reduction in IDRFs was seen in 81.8% of patients with average decrease of 2.9 ± 2.5 per patient. The average percent reduction in tumor volume was 89.8 ± 18.9% and correlated with the number of IDRFs present after chemotherapy (p < 0.01). Three or fewer IDRFs prior to surgery was associated with the highest odds ratio for > 90% GTR at 9.33 [95% confidence interval 3.14-31.5]. CONCLUSION: Neoadjuvant chemotherapy reduced the number of IDRFs in the majority of patients with high-risk neuroblastoma. The number of IDRFs present after neoadjuvant therapy correlated with the extent of resection.
Authors: Wolfgang Hiddemann; Michael Kneba; Martin Dreyling; Norbert Schmitz; Eva Lengfelder; Rudolf Schmits; Marcel Reiser; Bernd Metzner; Harriet Harder; Susanna Hegewisch-Becker; Thomas Fischer; Martin Kropff; Hans-Edgar Reis; Mathias Freund; Bernhard Wörmann; Roland Fuchs; Manfred Planker; Jörg Schimke; Hartmut Eimermacher; Lorenz Trümper; Ali Aldaoud; Reza Parwaresch; Michael Unterhalt Journal: Blood Date: 2005-08-25 Impact factor: 22.113
Authors: Victor M Santana; Wayne L Furman; Catherine A Billups; Fredric Hoffer; Andrew M Davidoff; Peter J Houghton; Clinton F Stewart Journal: J Clin Oncol Date: 2005-06-20 Impact factor: 44.544
Authors: Rajen Mody; Arlene Naranjo; Collin Van Ryn; Alice L Yu; Wendy B London; Barry L Shulkin; Marguerite T Parisi; Sabah-E-Noor Servaes; Mitchell B Diccianni; Paul M Sondel; Julia G Bender; John M Maris; Julie R Park; Rochelle Bagatell Journal: Lancet Oncol Date: 2017-05-23 Impact factor: 41.316
Authors: Y Tsuchida; J Yokoyama; M Kaneko; J Uchino; M Iwafuchi; S Makino; S Matsuyama; H Takahashi; I Okabe; K Hashizume Journal: J Pediatr Surg Date: 1992-05 Impact factor: 2.545
Authors: Andrew M Davidoff; Bethany L Corey; Fredric A Hoffer; Victor M Santana; Wayne L Furman; Stephen J Shochat Journal: Pediatr Blood Cancer Date: 2005-02 Impact factor: 3.167
Authors: Tom Monclair; Garrett M Brodeur; Peter F Ambros; Hervé J Brisse; Giovanni Cecchetto; Keith Holmes; Michio Kaneko; Wendy B London; Katherine K Matthay; Jed G Nuchtern; Dietrich von Schweinitz; Thorsten Simon; Susan L Cohn; Andrew D J Pearson Journal: J Clin Oncol Date: 2008-12-01 Impact factor: 44.544
Authors: G M Haase; M C O'Leary; N K Ramsay; S G Romansky; D O Stram; R C Seeger; G D Hammond Journal: J Pediatr Surg Date: 1991-09 Impact factor: 2.545
Authors: Janina Fischer; Alexandra Pohl; Ruth Volland; Barbara Hero; Martin Dübbers; Grigore Cernaianu; Frank Berthold; Dietrich von Schweinitz; Thorsten Simon Journal: BMC Cancer Date: 2017-08-04 Impact factor: 4.430